Menu
My ERA Rejoindre ERA

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial

Suggestions
My Era Rejoindre ERA
Home | Video pages | Webcast | SGLT2i for evidence based cardiorenal protection in diabetic and non-diabetic chronic kidney disease

SGLT2i for evidence based cardiorenal protection in diabetic and non-diabetic chronic kidney disease

Partager
https://www.youtube.com/watch?v=zHuzMXC52P0 copier

Access paper

SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EuReCa-M and ERBP Working Groups of ERA